Elicio Therapeutics announces a Trial in Progress poster presentation on the Phase 1/2 study of ELI-002 7P, a therapeutic cancer vaccine for patients with KRAS-mutated pancreatic ductal adenocarcinoma.
AI Assistant
ELICIO THERAPEUTICS INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.